Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations
Yan Li, Nianhang Chen, Maria Palmisano, Simon Zhou
Molecular Pharmaceutics, 2015
Abstract
This research paper explore the methodology and findings associated with Molecular Pharmaceutics. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
Related Research
- Preclinical antitumor activity of two novel taxanes 2001
- Pharmacokinetics of paclitaxel in patients with advanced ovarian cancer 2000
- Synthesis and Biological Evaluation of Paclitaxel Analogs 2001
- A Study on Pharmacokinetics of Compound Capsule of Paclitaxel in Rats 2011
- Effectiveness of nab-paclitaxel versus traditional paclitaxels in the treatment of ovarian cancer 2023
References
- Development of copolymers of poly(d,l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel 1999
- Pharmacokinetics and pharmacodynamics of <i>nab</i> ‐paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent‐based paclitaxel 2014
- Mechanism-Based Pharmacokinetic Model for Paclitaxel 2001
- Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer 2014
- Effects of Cremophor EL on distribution of Taxol to serum lipoproteins 1994